PATH | VRL
Menu

Safety and Immunogenicity of a Bivalent Group B Streptococcal Conjugate Vaccine for Serotypes II and III

This article, published in the Journal of Infectious Diseases, reports the results of a study to determine whether two monovalent group B Streptococcus (GBS) serotype II or III capsular polysaccharide-tetanus toxoid conjugate vaccines combined in a single intramuscular dose would elicit immune reponses comparable to those of monovalent vaccines. The vaccines were found to be well-tolerated and the results support the feasibility of a multivalent vaccine for the five prevalent invasive disease-causing GBS serotypes.

Author: Baker CJ, Rench MA, Fernandez M, Paoletti LC, Kasper DL, Edwards MS

Published: 2003

» Visit web page (English)

(Located at academic.oup.com)

Citation: Baker CJ, Rench MA, Fernandez M, Paoletti LC, Kasper DL, Edwards MS. Safety and Immunogenicity of a Bivalent Group B Streptococcal Conjugate Vaccine for Serotypes II and III. Journal of Infectious Diseases. 2003;188(1):66-73. 

Resource types: Peer-reviewed journal

Diseases/vaccines: Group B Streptococcus (GBS)

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Global